Biohaven muscle drug misses goal of SMA study, but advances in obesity

BioPharma Dive November 25, 2024
Ben Fidler

While Biohaven’s medicine may no longer be competitive in spinal muscular atrophy, the company saw enough potential for it as a weight loss treatment to plan a fast launch of a Phase 2 study.

Dive Brief:

• An experimental, muscle-preserving drug from Biohaven fell short of its goal in a Phase 3 study of people with spinal muscular atrophy, but showed enough promise in its effects on body composition that the company plans to advance it as a treatment for obesity.
• A regimen of Biohaven’s drug, taldefgrobep alfa, and a standard SMA therapy didn’t significantly improve motor function after 48 weeks compared to treatment with a typical SMA medicine and placebo. Biohaven didn’t provide full study data in a Monday...

Today's Sponsors

Today's Sponsor